Initial Capital Fund

BIB Seed Capital

We are a initial capital fund investing up to 1 million EUR in companies that operate in Poland. The funds will be spent on investments in companies that are in the initial stages of development (seed and start-up).

read more

We invest

The Initial Capital Fund "BIB Seed Capital" realizes investments that aim to apply the scientific and technological achievements of Polish scientists commercially, promote the transfer of technologies from Polish scientific units to small and medium-sized companies that operate in Poland.

We prefer investments in the earliest stages of development of the company - most importantly at the "start-up" stage, but that is not all.

Biotechnology and
molecular biology

Investment projects related to obtaining specialized chemical substances, including catalysts, preparing documentation as well as obtaining and production of generic medicines, specialized feed components, or plant care substances.

Pharmaceutical
chemistry

Investment projects related to obtaining specialized chemical substances, including catalysts, preparing documentation as well as obtaining and production of generic medicines, specialized feed components, or plant care substances.

Other projects
spanning multiple fields

that are realized at the edge of medicine, biology, chemistry, physics and informatics.

Objectives

Our objective is building an effective cooperation model between the spheres of science and business, leading to long-term mutual benefits (originator / fund) by making investments an raising the value of micro, small and middle-sized operational companies, which are in an early stage of their development or an expansion phase, that is which realized a phase of research or product or service development or have just finished that phase, but have not started commercial production and selling of the product or service and have not gained profits yet. We support enterprises that, thanks to the application of new achievements in science, allow for a satisfying return on the invested capital.

BIB Seed Capital uses various methods of acquiring projects. Among others:
  • cooperation with university and PAN partners;
  • cooperation with technology parks and the Data Processing Institute (OPI);
  • active monitoring of scientific environments that start R&D projects;
  • participation in and the Fund-sponsored organizing of investment conferences;
  • a business angel type of a program that offers rewards for a third party for indicating, evaluating or preparing an investment.
The creation of the Initial Capital Fund BIB Seed Capital influences the following:
  • ease and in most cases access to external sources of financing of micro and small companies that are in the early stages of operation;
  • ease of commercialization of scientific and technological achievements of Polish researchers thanks to easier access to business activity financing;
  • improvement of cooperation between science and business environments in transferring of technologies from Polish scientific units into the Polish economy.
  • accessibility of market verification of the value of Polish technological achievements.
  • changes in procedures in the scientific environment and increased pressure on support of research work in the industries related to a high economy potential.

Offer

Originator

Submitting the idea

Bib Seed Capital

Initial evaluation

Signing an NDA

Originator

Business plan

Bib Seed Capital

Evaluation of business plan

Signing a term sheet

Originator

Undergoing due diligence

Bib Seed Capital

Evaluation of enterprise

Signing investment agreement

Creating the company

Investment realized

The maximum investment amount is 1 million euro. The Fund is planning to realize at least 6 investment projects until June 30, 2008 in the so-called "new technologies" industry (IT, biotech, biomed).

Projects

Team

Marcin Hoffmann

Marcin Hoffmann

CEO of the fund, member of the Fund's investment Committee

Doctorate in Chemistry, graduated from biotechnology studies at the Biological Department of UAM, in 2000 MBA (Georgia State University Atlanta and the Economic Academy in Poznań). In the years 2001-2002 he studied with a stipend for young doctors from the Foundation for Polish Science at the University of Emory in Atlanta.

In the years 2002-2003 he worked as a consultant in McKinsey & Co in Warsaw, where he participated in projects related to the telecommunications sector and energy carriers.

Since 2004 he has been the chief investment and development officer at BioInfoBank sp. z o.o. He is responsible for running the part of the company that is dedicated to investing in newly created innovative companies. He was responsible for conducting investments and support of the initial phases of IT and biotechnological companies. He is responsible for supporting the formulation of financial strategies and forecasts. A finalized disinvestment in one of the companies allowed for a return of 50% in the investment.

Besides directing the investment part of BioInfoBank, he leads a research team dedicated to development of diagnostic methods and a substance against the SARS coronavirus as part of a Chinese-European consortium of research institutes and biotechnological companies.

Thanks to his scientific and business experience, he can efficiently communicate with scientists and businessmen alike and has the knowledge and experience related to the needs of the commercial uses of scientific research from the innovative solution creation stage by evaluating its commercial potential, formulating the product strategy, organizing an innovative company and its development.

Leszek Rychlewski

Leszek Rychlewski

Member of the Fund's Investment Committee.

Graduated from medical school in Berlin and later worked in San Diego, where he conducted bioinformatics research. In 200 he returned to Poland, where he conducted bioinformatics research in the International Institute of Molecular Biology. He has co-authored about 100 scientific papers.

He is the founder and the only investor of BioInfoBank Sp. z o.o., as well as Instytut BioInfoBank, which conducts research in the field of bioinformatics. He decided to create a separate part of the company to handle investments in newly created innovative bioinformatics and pharmaceutical enterprises. A finalized disinvestment in one of the companies allowed for a return of 50% in the investment. He organizes cooperation between researchers and businesses (he is, among others, the coordinator of the Centrum Doskonałości CITech (Centrum Innowacyjnych Technologii) which cooperates with scientific laboratories and bioinformatics enterprises).

He has realized and is currently realizing 8 projects of the European Commission-funded 5th and 6th Program for the total value of over 20 million euro (including the budget of the European partners). His scientific and business experience allow L. Rychlewski to possess extensive knowledge on topics related to development and functioning of innovative bioinformatics enterprises in Poland.

Contact

BIB Seed Capital is in the Poznań Regional Court enterprise registry, VIII WG KRS, no. 0000379911

BIB Seed Capital s.a.

ul. Św. Marcin 80/82 lok. 355

61-809 Poznań

tel/fax: (+48 61) 852 49 46


e-mail: seed@bioinfo.pl


NIP: 972 115 67 19

Regon: 300574097